{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009137","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.481472+00:00","generated_at":"2026-06-25T21:10:04.088947+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q1 net loss $25.2M; cash $449.9M; TNG908 trial open","bullets":["Net loss $25.2M ($0.29/share) vs $12.1M loss in Q1 2021; R&D expense $24.3M (+62% YoY).","Cash, cash equivalents & marketable securities $449.9M; expected to fund operations into H2 2024.","TNG908 Phase 1/2 trial open for MTAP-deleted solid tumors; FDA Fast Track Designation granted.","Declared TNG462 (next-gen PRMT5 inhibitor) and TNG260 (STK11-loss inhibitor) as development candidates.","Collaboration revenue $5.8M, down from $6.4M, due to lower Gilead research costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009137","json":"https://secwatch.observer/filing/0000950170-22-009137.json","markdown":"https://secwatch.observer/filing/0000950170-22-009137.md","text":"https://secwatch.observer/filing/0000950170-22-009137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/0000950170-22-009137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/tngx-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:10:04.088947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}